Any physician treating cardiac arrhythmias should be aware of a possible worsening of the arrhythmia (so-called arrhythmogenesis) after the start of antiarrhythmic drug treatment. To facilitate the recognition of that complication the type and possible mechanisms of arrhythmogenesis are reviewed. Recognition also requires an understanding of (a) the time of appearance of arrhythmogenic effects after different drugs, (b) the value of non-invasive and invasive tests, and (c) the profile of the patient most likely to develop this problem. Guidelines are given to reduce the incidence of the arrhythmogenic effects of antiarrhythmic drugs and a plea is made that the physician should be always on the alert for this complication.
Many thousands of patients are taking medication because of a cardiac arrhythmia. There is increasing awareness that approximately 15% of patients show worsening of their arrhythmia or the appearance of a new arrhythmia after they have started antiarrhythmic drug treatment. This so-called arrhythmogenic effect or arrhythmogenesis can be life-threatening.'
The results of the CAST study89 also made the public aware of the possible dangers of antiarrhythmic drug treatment. Physicians treating cardiac arrhythmias need to be familiar with the risk of drug treatment and to be able to recognise it. We suggest a practical approach to the different types of arrhythmogenesis that may develop after antiarrhythmic drug administration and we briefly review the possible types and mechanisms of arrhythmogenesis, which have been discussed extensively elsewhere.5
We also discuss the timing of the appearance of arrhythmogenesis after start of antiarrhythmic drug treatment, discuss the value of different non-invasive and invasive tests to document arrhythmogenesis or to recognise patients at an increased risk of developing this problem, and offer guidelines to reduce its incidence.
Types and possible mechanisms of arrhythmogenesis It is useful to classify the different types of arrhythmogenic effects '7 (table 1) because it facilitates their recognition and may help to identify possible mechanisms.
WORSENING OF AN ALREADY MANIFEST ARRHYTHMIA
After antiarrhythmic drug administration the same arrhythmia may occur more frequently, last longer or become less well tolerated because the rate increases. Table 2 shows that this category includes patients with isolated ventricular extrasystoles or non-sustained ventricular tachycardia in whom sustained ( fig  1) or even incessant ventricular tachycardia subsequently develops. Patients with atrial flutter and atrial fibrillation in whom druginduced slowing of the atrial rate results in more atrial impulses being conducted through the atrioventricular node also belong to this category ( fig 2) .
Facilitation of unidirectional block and of slowing in conduction velocity within the reentry circuit are the most likely mechanisms for drug-induced worsening of an arrhythmia based upon reentry. By slowing intraventricular conduction class Ia and Ic drugs can example of this phenomenon in a patient who was treated with a class Ic agent because of a non-sustained ventricular tachycardia. During administration of the antiarrhythmic drug the patient noticed that a sustained tachycardia always developed when he exercised. Figure 10 shows that during exercise testing the QRS complex and axis deviation increased considerably and was followed by sustained ventricular tachycardia. Exercise related ventricular tachycardia no longer occurred in this patient when the class Ic agent was replaced by a class III drug. During exercise testing off drugs Kadish et al.24 found a paradoxical increase in the corrected QT interval in patients who had arrhythmogenic effects on a type Ia drug. Antiarrhythmic drugs may not only produce use-dependent slowing in conduction but also use-dependent prolongation of the refractory period. Figures 1 1 and 12 show that in a patient with right bundle branch block and left anterior hemiblock a rate-related (use-depen- 
Conclusions
Antiarrhythmic agents commonly, have arrhythmogenic effects that are life-threatening and these can occur as long as the patient is taking antiarrhythmic medication. Although, as outlined, certain measures can be taken to minimise the chance of arrhythmogenic effects, the patient and the physician should constantly be alert to this possibility. 
